Physician
Oncology
Dr. Srdan Verstovsek, MD
|
|
Give Review
Srdan Verstovsek works in the field of Oncology. Srdan Verstovsek, MD is a published doctor as well. He has 87 publications published. The latest was: Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes. He accepts Medicare payments and is registered with Medicare.gov.
Publications
- The evolution and clinical relevance of prognostic classification Systems in myelofibrosis.
- Analysis of 2013 European LeukaemiaNet (ELN) responses in Chronic phase CML across four frontline TKI modalities and impact on clinical outcomes.
- A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed Acute myeloid leukemia and high-risk myelodysplastic syndrome.
- Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML).
- Clinical Validation of a Multipurpose Assay for Detection and Genotyping of CALR Mutations in Myeloproliferative Neoplasms.
- Efficacy of ruxolitinib on hepatomegaly in patients with myelofibrosis.
- Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors.
- The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis.
- Increased likelihood of post-polycythemia vera myelofibrosis in Ph-negative MPN patients with chromosome 12 abnormalities.
- Durable remission with rituximab in a patient with an unusual variant of Castleman's Disease with myelofibrosis -TAFRO syndrome.
- Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis.
- Novel and emerging therapies for the treatment of polycythemia vera.
- Long non-coding RNAs in primary myelofibrosis: the dark matter in hematopoietic progenitor Cells?
- Phase II evaluation of IPI-926, an Oral Hedgehog inhibitor, in patients with myelofibrosis.
- Ruxolitinib versus standard therapy for the treatment of polycythemia vera.
- Three-year efficacy, overall survival, and safety of ruxolitinib therapy in patients with myelofibrosis from the COMFORT-I study.
- Mechanisms of thrombogenesis in polycythemia vera.
- A phase I, open-label, multi-center study of the JAK2 inhibitor AZD1480 in patients with myelofibrosis.
- Impact of Bone Marrow Pathology on the Clinical Management of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
- Clinical characteristics and outcomes in patients with Acute promyelocytic leukaemia and hyperleucocytosis.
- A Phase I/II Study of the Janus Kinase (JAK)1 and 2 Inhibitor Ruxolitinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia.
- Ruxolitinib and survival improvement in patients with myelofibrosis.
- Flow cytometric immunophenotypic analysis of Systemic mastocytosis involving bone marrow.
- Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant Anemia.
- Clinical significance of microcytosis in patients with primary myelofibrosis.
- Ruxolitinib and DNA methyltransferase-inhibitors: a foray into combination regimens in myelofibrosis.
- Comorbidities predict worse prognosis in patients with primary myelofibrosis.
- ETV6-FLT3 fusion gene-positive, eosinophilia-associated myeloproliferative neoplasm successfully treated with sorafenib and allogeneic stem Cell transplant.
- Stimulation of the B-cell receptor activates the JAK2/STAT3 signaling pathway in chronic lymphocytic Leukemia cells.
- Use of the Functional Assessment of Cancer Therapy-Anemia in Persons with Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia.
- Atypical chronic myeloid Leukemia (aCML) BCR-ABL1-negative is clinicopathologically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms (MDS/MPN-...
- Janus Kinase Inhibitors and Allogeneic Stem Cell Transplantation for Myelofibrosis.
- Myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN, U): natural history and clinical outcome by treatment strategy.
- Paroxysmal nocturnal hemoglobinuria is not a cause of Anemia in patients with myelofibrosis.
- Phase I evaluation of XL019, an Oral, potent, and selective JAK2 inhibitor.
- A Phase I and Pharmacodynamic Study of AT9283, a Small-Molecule Inhibitor of Aurora Kinases in Patients With Relapsed/Refractory Leukemia or Myelofibrosis.
- Bone marrow fibrosis in patients with primary myelodysplastic syndromes has prognostic value using current therapies and new risk stratification Systems.
- Imatinib therapy in a patient with suspected chronic neutrophilic Leukemia and FIP1L1-PDGFRA rearrangement.
- Discrepancy in diagnosis of primary myelofibrosis between referral and tertiary care centers.
- Acute Myeloid Leukemia After Myelodysplastic Syndrome and Failure of Therapy With Hypomethylating Agents: An Emerging Entity With a Poor Prognosis.
- Metastatic splenic angiosarcoma presenting with thrombocytopenia and bone marrow fibrosis mimicking idiopathic thrombocytopenic purpura and primary myelofibrosis: a di...
- Primary autoimmune myelofibrosis (MF) with high-grade peripheral T-Cell lymphoma (PTCL) NOS.
- A phase 2 study of ruxolitinib, an Oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea.
- Similar Outcome of Patients With Chronic Myeloid Leukemia Treated With Imatinib in or Out of Clinical Trials.
- JAK2 p.V617F detection and allele burden measurement in peripheral blood and bone marrow aspirates in patients with Myeloproliferative neoplasms.
- Patients with polycythemia vera and essential thrombocythemia with prior malignancy do not have significantly worse outcome.
- Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies.
- Significance of deeper molecular responses in patients with chronic myeloid Leukemia in early chronic phase treated with tyrosine kinase inhibitors.
- Tips on using ruxolitinib in everyday practice as therapy for myelofibrosis.
- Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies.
- Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a.
- Outcome After Failure of Second Generation Tyrosine Kinase Inhibitors Treatment As First-line Therapy for Patients With Chronic Myeloid Leukemia.
- Modest activity of pomalidomide in patients with myelofibrosis and significant Anemia.
- A phase II open-label study of the intravenous administration of homoharringtonine in the treatment of Myelodysplastic syndrome.
- The clinical importance of moderate/severe bone marrow fibrosis in patients with therapy-related Myelodysplastic syndromes.
- Progressive burden of myelofibrosis in untreated patients: Assessment of patient-reported outcomes in patients randomized to placebo in the COMFORT-I study.
- Effect of Ruxolitinib Therapy on Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in COMFORT-I: A Randomized, Double-Blind, Placebo-Controlled Trial.
- Early responses predicts for better outcomes in patients with newly diagnosed CML: results with four TKI modalities.
- Systemic mastocytosis with associated clonal hematological non-mast Cell lineage disease: Clinical significance and comparison of chomosomal abnormalities in SM and AH...
- What is next beyond janus kinase 2 inhibitors for primary myelofibrosis?
- The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis.
- Prognostic implications and clinical characteristics associated with bone marrow fibrosis in patients with myelofibrosis.
- Molecular Pathways: JAK/STAT PATHWAY: MUTATIONS, INHIBITORS, AND RESISTANCE.
- Chromosome 5q deletion is extremely rare in patients with myelofibrosis.
- Bone marrow mast Cell burden and serum tryptase level as markers of response in patients with systemic mastocytosis.
- The Role of JAK Pathway Dysregulation in the Pathogenesis and Treatment of Acute Myeloid Leukemia.
- Ruxolitinib: an Oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis.
- An unusual case of aggressive systemic mastocytosis with associated refractory plasma Cell myeloma.
- Advanced Systemic mastocytosis: the impact of KIT mutations in diagnosis, treatment, and progression.
- Long-Term Follow-up of Patients With Hypereosinophilic Syndrome Treated With Alemtuzumab, an Anti-CD52 Antibody.
- Therapeutic effects of ruxolitinib in patients with myelofibrosis without clinically significant splenomegaly.
- Biology and Clinical Management of Myeloproliferative Neoplasms and Development of the JAK Inhibitor Ruxolitinib.
- Analysis of outcomes in adolescents and young adults with chronic myelogenous Leukemia treated with upfront tyrosine kinase inhibitor therapy.
- Long term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls.
- Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm Acute myeloid leukemia.
- JAK2 Inhibitors for Myelofibrosis: Why Are They Effective in Patients With and Without JAK2V617F Mutation?
- Prognostic significance of CD20 expression in adults with de novo precursor B-lineage Acute lymphoblastic leukemia.
- Hepatosplenic gamma-delta T-Cell lymphoma: clinicopathological features and treatment.
- Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a p...
- The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during Disease course.
- Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid Leukemia after cytogenetic failure on standard-dose imatinib th...
- Effective treatment of Acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin.
- Clofarabine combinations as Acute myeloid leukemia salvage therapy.
- Extramedullary Acute myeloid leukemia: leukemic pleural effusion, case report and review of the literature.
- Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes.
- Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes.
Procedures Preformed
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anemia
- Basal Cell Carcinoma
- Bladder Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
University of Texas Health Science Center -
University at Buffalo -
University of Zagreb Faculty of Medicine
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1598864100 | |
| NPPES Provider LastName | VERSTOVSEK | |
| NPPES Provider FirstName | SRDAN | |
| NPPES Provider ZIPCode | 770304009 | |
| NPPES Provider State | TX | |
| Specialty Description | Internal Medicine | |
| Total Claim Count | 630.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 34.0 | |
| Percent Opioid Claims | 5.4 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1598864100 |
| Last Name Of The Provider | VERSTOVSEK |
| First Name Of The Provider | SRDAN |
| View All |
Similar Doctors
|
|
Dr. Paolo Anderlini, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rachna Shroff, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Anne Tsao, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nicholas E. Papadopoulos, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Yee L. Tham, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mindy Hsiong, MD
This Doctor is OpenDoctor Recommended.
|